Vascular Biogenics Ltd.
NASDAQ:VBLT
0.15 (USD) • At close October 16, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Vascular Biogenics Ltd. |
Symbool | VBLT |
Munteenheid | USD |
Prijs | 0.156 |
Beurswaarde | 12,111,917 |
Dividendpercentage | 0% |
52-weken bereik | 0.101 - 0.32 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Prof. Dror Harats M.D. |
Website | https://www.vblrx.com |
An error occurred while fetching data.
Over Vascular Biogenics Ltd.
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)